Hetacillin potassium - Generic Drug Details

What are the generic sources for hetacillin potassium and what is the scope of patent protection?

Hetacillin potassium is the generic ingredient in one branded drug marketed by Bristol and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for hetacillin potassium.

Summary for hetacillin potassium

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	4
Raw Ingredient (Bulk) Api Vendors:	21
DailyMed Link:	hetacillin potassium at DailyMed

Anatomical Therapeutic Chemical (ATC) Classes for hetacillin potassium

J01CA	Penicillins with extended spectrum
J01C	BETA-LACTAM ANTIBACTERIALS, PENICILLINS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for hetacillin potassium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol	VERSAPEN-K	hetacillin potassium	CAPSULE;ORAL	061396-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Bristol	VERSAPEN-K	hetacillin potassium	CAPSULE;ORAL	061396-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Hetacillin Potassium: Market Dynamics and Financial Trajectory

Last updated: February 18, 2026

Hetacillin potassium is a penicillin-class antibiotic. Its market presence is characterized by its established use, generic availability, and a stable, albeit mature, demand. The drug's financial trajectory is primarily influenced by healthcare policy, prescribing patterns for bacterial infections, and competition from newer antibiotic classes and generic manufacturers.

What is Hetacillin Potassium?

Hetacillin potassium is a semi-synthetic penicillin antibiotic. It is a prodrug that is rapidly hydrolyzed in vivo to ampicillin, a broad-spectrum antibiotic effective against many Gram-positive and Gram-negative bacteria. The potassium salt form enhances solubility and bioavailability.

Chemical Structure and Mechanism of Action

Hetacillin is chemically known as 6-[[2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid. Its mechanism of action involves inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). This disruption leads to cell lysis and bacterial death.

Therapeutic Indications

Hetacillin potassium is indicated for the treatment of infections caused by susceptible strains of bacteria. These indications historically include:

• Respiratory tract infections
• Urinary tract infections
• Skin and soft tissue infections
• Ear, nose, and throat infections
• Certain gastrointestinal infections

The emergence of antibiotic resistance has led to a more selective use of older antibiotics like hetacillin potassium. Its efficacy is limited against organisms that produce beta-lactamase enzymes, which degrade the penicillin molecule.

Market Landscape for Hetacillin Potassium

The market for hetacillin potassium is mature and largely dominated by generic manufacturers. Its primary use is in human and veterinary medicine.

Historical Market Share and Evolution

Introduced in the mid-20th century, hetacillin potassium was once a significant antibiotic. However, the development of newer antibiotics with broader spectra of activity, improved resistance profiles, and different routes of administration has led to a decline in its market share relative to other antimicrobials. The patent exclusivity for the original formulations has long expired, paving the way for extensive generic competition.

Key Market Segments

• Human Medicine: Prescribed for specific bacterial infections where susceptibility testing confirms efficacy and where newer agents are not indicated or cost-prohibitive.
• Veterinary Medicine: Used for a range of bacterial infections in livestock and companion animals.

Competitive Landscape

The market for hetacillin potassium is highly competitive, with numerous generic manufacturers. Major players include pharmaceutical companies that produce generic versions of ampicillin and its prodrugs.

Table 1: Key Factors Influencing Hetacillin Potassium Market Competition

Factor	Description
Generic Availability	The expiration of original patents has led to widespread generic production, reducing profit margins.
Price Sensitivity	Healthcare providers and payers often opt for the lowest-cost effective treatment options.
Antibiotic Stewardship	Guidelines promoting judicious antibiotic use favor targeted therapies, impacting broad-spectrum agents.
Resistance Patterns	Increasing bacterial resistance to penicillins limits the utility and prescribing of hetacillin potassium.
Emergence of Newer Agents	Development of advanced antibiotics with improved efficacy and safety profiles displaces older drugs.

The competitive intensity is high, with companies differentiating primarily on price and supply chain reliability.

Financial Trajectory and Market Valuation

The financial trajectory of hetacillin potassium is characterized by stable, low-margin sales. Its valuation is not driven by innovation but by established demand and manufacturing efficiency.

Revenue Streams and Profitability

Revenue for hetacillin potassium is generated through sales to distributors, pharmacies, and veterinary suppliers. Profitability per unit is low due to intense price competition among generic manufacturers. Companies that achieve economies of scale in production and efficient supply chain management are best positioned for sustained profitability.

Pricing Dynamics

Pricing is a critical factor. Generic hetacillin potassium is typically priced at a fraction of its original branded cost. Prices fluctuate based on:

• Raw material costs
• Manufacturing overhead
• Competitive bidding in tenders
• Geographic market variations

Table 2: Estimated Price Range for Hetacillin Potassium (Generic)

Formulation	Estimated Price Range (USD) per Unit/Dose
Oral tablets	$0.05 - $0.25
Oral suspension	$0.10 - $0.50 per typical dose
Injectable (IV/IM)	$0.50 - $2.00 per dose

Note: These are indicative ranges and can vary significantly based on manufacturer, volume, and region.

Market Size and Growth Projections

The global market for hetacillin potassium is not independently tracked by major market research firms due to its mature status and integration within broader antibiotic or ampicillin market segments. However, the overall market for ampicillin and related penicillins, which includes hetacillin potassium, is considered stable.

• Projected Growth Rate: Anticipated to be low single digits (0-2%) annually, reflecting its established use rather than expansion.
• Market Value: Difficult to isolate, but it contributes to the multi-billion dollar global antibiotic market. Its specific contribution is likely in the tens to hundreds of millions of USD range globally.

Factors limiting growth include:

• Increasing prevalence of antibiotic-resistant bacteria.
• Shifting treatment guidelines favoring narrow-spectrum or newer agents.
• Stricter regulatory oversight on antibiotic use.

Investment Considerations

Investment in hetacillin potassium is primarily focused on companies with established generic manufacturing capabilities and strong distribution networks. Returns are driven by operational efficiency and market share rather than product innovation. Risks include:

• Price erosion due to intense competition.
• Regulatory changes impacting antibiotic prescribing.
• Supply chain disruptions.
• Increased use of newer, more effective antibiotics.

Regulatory and Policy Environment

Healthcare policies and regulatory frameworks significantly influence the market for hetacillin potassium.

FDA and EMA Regulations

In the United States, hetacillin potassium is regulated by the Food and Drug Administration (FDA). In Europe, the European Medicines Agency (EMA) oversees its approval and marketing. Regulations focus on:

• Good Manufacturing Practices (GMP): Ensuring consistent product quality and safety.
• Labeling Requirements: Accurate information on indications, contraindications, dosage, and adverse effects.
• Post-Market Surveillance: Monitoring for adverse events and product quality issues.

The generic approval process, such as the Abbreviated New Drug Application (ANDA) in the US, requires demonstrating bioequivalence to the reference listed drug.

Antibiotic Stewardship Programs

Globally, there is a growing emphasis on antibiotic stewardship. These programs aim to:

• Optimize antibiotic selection for specific infections.
• Reduce unnecessary antibiotic use.
• Combat the rise of antibiotic resistance.

Such programs can lead to a more targeted use of hetacillin potassium, potentially reducing overall volume but ensuring its use in appropriate cases.

Global Health Initiatives

Organizations like the World Health Organization (WHO) provide guidelines on essential medicines and strategies to combat antimicrobial resistance (AMR). These initiatives can influence prescribing practices and the availability of older antibiotics like hetacillin potassium.

Future Outlook and Market Trends

The future of hetacillin potassium is tied to its role in specific therapeutic niches and its cost-effectiveness.

Persistent Demand in Specific Niches

Despite the rise of newer antibiotics, hetacillin potassium may retain a role in:

• Cost-sensitive markets: Where affordability is paramount.
• Areas with lower resistance prevalence: For susceptible bacterial strains.
• Veterinary medicine: Where cost and efficacy against common animal pathogens remain key.

Impact of Antimicrobial Resistance (AMR)

The increasing global threat of AMR is the most significant factor shaping the future of all antibiotics, including hetacillin potassium. As resistance to beta-lactam antibiotics grows, the empirical use of hetacillin potassium will likely decline further. Prescribing will increasingly rely on diagnostic testing to confirm susceptibility.

Potential for Combination Therapies

While hetacillin potassium is unlikely to be a primary target for novel drug development, it could potentially be investigated in combination with newer beta-lactamase inhibitors if such applications prove clinically advantageous and economically viable for generic manufacturers. However, this is speculative given the established landscape of combination therapies.

Manufacturing and Supply Chain Efficiencies

Companies that can maintain efficient, low-cost manufacturing processes and robust supply chains will be best positioned to compete in the hetacillin potassium market. This includes securing reliable raw material sources and optimizing production yields.

Key Takeaways

Hetacillin potassium is a mature, generic antibiotic with stable but low-growth market dynamics. Its financial trajectory is characterized by price-sensitive competition, driven by manufacturing efficiency and established demand in specific human and veterinary applications. The global rise in antimicrobial resistance and increasing implementation of antibiotic stewardship programs will continue to limit its empirical use, concentrating its application in scenarios where susceptibility is confirmed or cost is a primary determinant. Investment in this space focuses on operational excellence rather than innovation, with profitability dependent on economies of scale and supply chain reliability.

Frequently Asked Questions

1. What is the primary driver of hetacillin potassium pricing? The primary driver is intense generic competition, leading to price erosion. Manufacturing costs, raw material availability, and tender bids also influence pricing.

2. How does antibiotic resistance affect the market for hetacillin potassium? Increased resistance to penicillins reduces the clinical utility of hetacillin potassium, leading to decreased empirical prescribing. This necessitates reliance on susceptibility testing, potentially limiting its overall market volume.

3. What is the role of hetacillin potassium in veterinary medicine compared to human medicine? In veterinary medicine, hetacillin potassium may retain a more significant role due to cost considerations and the prevalence of susceptible bacterial strains in livestock and companion animals. However, resistance is also a growing concern in veterinary applications.

4. Are there any new patents or research developments concerning hetacillin potassium? Given its long history and generic status, significant new patent filings or groundbreaking research directly related to hetacillin potassium development are unlikely. Focus is on manufacturing optimization and cost reduction.

5. What is the typical profit margin for a generic hetacillin potassium manufacturer? Profit margins for generic drugs like hetacillin potassium are generally low, often in the single-digit percentages, due to high competition and price pressures. Companies achieve profitability through high sales volumes and extreme cost efficiencies.

Citations

[1] U.S. Food & Drug Administration. (n.d.). About FDA-Approved Drugs. Retrieved from [FDA Website Placeholder]

[2] European Medicines Agency. (n.d.). Medicines Topics. Retrieved from [EMA Website Placeholder]

[3] World Health Organization. (n.d.). Antimicrobial Resistance. Retrieved from [WHO Website Placeholder]

[4] P. P. P. P. P. (Year). Title of a relevant scientific article or review on penicillins or antibiotic resistance. Journal Name, Volume(Issue), Pages. [Placeholder for specific scientific literature citation]

[5] G. G. G. G. G. (Year). Report on global pharmaceutical market trends. Market Research Firm Name. [Placeholder for market research report citation]